Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin 40 mg versus 80 mg in acute coronary syndrome
IRCT20140921019240N4Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin in acute coronary syndrome (ACS) (2 arms), sponsored by Sabzevar University of Medical Sciences. Primary endpoints: Effective dose of atorvastatin in acute coronary syndrome and Reduction in LDL cholesterol. Started Jun 2018; status: completed.
02
Drugs
atorvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20140921019240N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140921019240N4.